Article Details

Argenx Scores Priority Review for Generalized Myasthenia Gravis Therapeutic - BioSpace

Retrieved on: 2022-11-22 23:39:30

Tags for this article:

Click the tags to see associated articles and topics

Argenx Scores Priority Review for Generalized Myasthenia Gravis Therapeutic - BioSpace. View article details on HISWAI: https://www.biospace.com/article/fda-grants-argenx-s-subcutaneous-injectable-drug-priority-review-for-generalized-myasthenia-gravis/

Excerpt

Additional therapies include monoclonal antibodies such as Genentech and Biogen's Rituxan (rituximab) and AstraZeneca/Alexion's Soliris ...

Article found on: www.biospace.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up